What have we learned from large drug treatment trials in COPD?
- 7 September 2007
- journal article
- review article
- Published by Elsevier in The Lancet
- Vol. 370 (9589) , 774-785
- https://doi.org/10.1016/s0140-6736(07)61381-6
Abstract
No abstract availableKeywords
This publication has 101 references indexed in Scilit:
- Mortality in COPD: role of comorbiditiesEuropean Respiratory Journal, 2006
- Reduction of Morbidity and Mortality by Statins, Angiotensin-Converting Enzyme Inhibitors, and Angiotensin Receptor Blockers in Patients With Chronic Obstructive Pulmonary DiseaseJournal of the American College of Cardiology, 2006
- Addition of salmeterol to existing treatment in patients with COPD: a 12 month studyThorax, 2006
- Clinical Practice Guidelines and Quality of Care for Older Patients With Multiple Comorbid DiseasesJAMA, 2005
- Bronchodilator response in the lung health study over 11 yrsEuropean Respiratory Journal, 2005
- Maintenance therapy with budesonide and formoterol in chronicobstructive pulmonary diseaseEuropean Respiratory Journal, 2003
- Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trialThe Lancet, 2003
- Health status measurement in chronic obstructive pulmonary diseaseThorax, 2001
- Factors associated with relapse after ambulatory treatment of acute exacerbations of chronic bronchitisEuropean Respiratory Journal, 2001
- Variability of bronchodilator response and effects of inhaled corticosteroid treatment in obstructive airways disease. Dutch CNSLD Study Group.Thorax, 1993